All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: Tagrisso
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 29, 2021
Details:
In this exploratory analysis of the overall trial population, adjuvant Tagrisso reduced the risk of disease recurrence or death by 84% in patients who had been treated with prior adjuvant chemotherapy and by 77% in patients who had not.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Acalabrutinib
Therapeutic Area: Oncology Product Name: Calquence
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2021
Details:
Positive high-level results from the ELEVATE-RR Phase III trial showed AstraZeneca’s Calquence met the primary endpoint showing non-inferior progression-free survival for adults with previously treated, high-risk chronic lymphocytic leukaemia compared to ibrutinib.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Durvalumab
Therapeutic Area: Oncology Product Name: Imfinzi
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 15, 2021
Details:
AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union and the UK for an additional dosing option, a 1,500mg fixed dose every four weeks, in locally advanced, unresectable non-small cell lung cancer.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Olaparib,Bevacizumab
Therapeutic Area: Oncology Product Name: Lynparza
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co. Inc.
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 28, 2020
Details:
Approvals of Lynparza in Three Types of Cancer are based on the PAOLA-1, PROfound and POLO Phase 3 Trials
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
